Table 1 Patient clinical characteristics
| Â | Level | Overall | Training cases | Validation cases | External validation cases |
|---|---|---|---|---|---|
Number | Â | 243 | 128 | 64 | 51 |
Patient age (%) | Younger (≤ 50) | 144 (59.3) | 79 (61.7) | 36 (56.2) | 29 (56.9) |
Older (> 50) | 99 (40.7) | 49 (38.3) | 28 (43.8) | 22 (43.1) | |
Tumor stage (%) | Stage I–II | 117 (48.1) | 51 (39.8) | 25 (39.1) | 41 (80.4) |
Stage III | 126 (51.9) | 77 (60.2) | 39 (60.9) | 10 (19.6) | |
Mulecular subtypes (%) | Her2 +  | 47 (19.3) | 28 (21.9) | 10 (15.6) | 9 (17.6) |
luminal A | 52 (21.4) | 21 (16.4) | 12 (18.8) | 19 (37.3) | |
luminal B (Her2 −) | 57 (23.5) | 32 (25.0) | 20 (31.2) | 5 (9.8) | |
luminal B (Her2 +) | 44 (18.1) | 28 (21.9) | 13 (20.3) | 3 (5.9) | |
TNBC | 43 (17.7) | 19 (14.8) | 9 (14.1) | 15 (29.4) | |
Ki67 expression (%)a |  ≤ 20% | 78 (32.2) | 34 (26.8) | 20 (31.2) | 24 (47.1) |
 > 20% | 164 (67.8) | 93 (73.2) | 44 (68.8) | 27 (52.9) | |
Menstrual status (%) | Postmenopausal | 149 (61.3) | 85 (66.4) | 40 (62.5) | 24 (47.1) |
Premenopausal | 94 (38.7) | 43 (33.6) | 24 (37.5) | 27 (52.9) | |
Response to NAC, MP (%) | 1 | 18 (7.4) | 8 (6.2) | 5 (7.8) | 5 (9.8) |
2 | 52 (21.4) | 25 (19.5) | 13 (20.3) | 14 (27.5) | |
3 | 51 (21.0) | 25 (19.5) | 15 (23.4) | 11 (21.6) | |
4 | 41 (16.9) | 27 (21.1) | 11 (17.2) | 3 (5.9) | |
5 | 81 (33.3) | 43 (33.6) | 20 (31.2) | 18 (35.3) | |
Response to NAC, RCB (%) | pCR | 61 (25.1) | 32 (25.0) | 16 (25.0) | 13 (25.5) |
RCB I | 29 (11.9) | 17 (13.3) | 8 (12.5) | 4 (7.8) | |
RCB II | 87 (35.8) | 49 (38.3) | 21 (32.8) | 17 (33.3) | |
RCB III | 66 (27.2) | 30 (23.4) | 19 (29.7) | 17 (33.3) | |
Treatment regimen (%) | EC | 14 (5.8) | 6 (4.7) | 7 (10.9) | 1 (2.0) |
EC-T (H/HP), T(H)-EC, TEC | 212 (87.2) | 112 (87.5) | 56 (87.5) | 44 (86.3) | |
T(HP), TC(H), TCbH(P) | 17 (7.0) | 10 (7.8) | 1 (1.6) | 6 (11.8) |